Sarepta Therapeutics Target of Unusually High Options Trading (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) was the recipient of some unusual options trading on Friday. Stock investors acquired 15,859 call options on the stock. This represents an increase of 355% compared to the average daily volume of 3,486 call options.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on SRPT shares. Deutsche Bank Aktiengesellschaft dropped their price objective on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a research report on Wednesday, March 19th. Scotiabank reduced their price objective on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a research note on Thursday, March 20th. Needham & Company LLC lowered their price target on shares of Sarepta Therapeutics from $183.00 to $125.00 and set a “buy” rating on the stock in a report on Wednesday. Wells Fargo & Company dropped their price objective on Sarepta Therapeutics from $115.00 to $100.00 and set an “overweight” rating for the company in a research note on Thursday. Finally, Piper Sandler cut their target price on shares of Sarepta Therapeutics from $110.00 to $70.00 and set an “overweight” rating for the company in a research note on Wednesday. Six research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $131.22.

Sarepta Therapeutics Price Performance

SRPT opened at $36.27 on Friday. The stock has a market cap of $3.56 billion, a P/E ratio of 29.02 and a beta of 0.85. Sarepta Therapeutics has a 52-week low of $35.46 and a 52-week high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The business has a fifty day moving average of $66.84 and a 200 day moving average of $100.86.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). The firm had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The company’s revenue for the quarter was up 80.2% on a year-over-year basis. During the same period last year, the firm earned $0.73 earnings per share. As a group, sell-side analysts anticipate that Sarepta Therapeutics will post 2.67 EPS for the current year.

Insider Activity

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the sale, the director now owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Several large investors have recently modified their holdings of the business. Manchester Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its stake in Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 156 shares during the period. Byrne Asset Management LLC purchased a new stake in Sarepta Therapeutics in the first quarter valued at $30,000. Center for Financial Planning Inc. purchased a new stake in shares of Sarepta Therapeutics in the first quarter worth about $31,000. Finally, Newbridge Financial Services Group Inc. acquired a new stake in shares of Sarepta Therapeutics during the 4th quarter worth approximately $36,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.